{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=ADD&page=34", "query": { "condition": "ADD", "page": 34 }, "page_size": 10 }, "pagination": { "page": 34, "page_size": 10, "total_count": 2226, "total_pages": 223, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=ADD&page=35&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=ADD&page=33&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-29T20:06:47.531Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07044544", "title": "Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Myeloid Malignancy", "Hematologic Malignancy", "Acute Myeloid Leukemia", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "G-CSF", "type": "DRUG" }, { "name": "Decitabine", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 20, "start_date": "2025-07-17", "completion_date": "2027-01", "has_results": false, "last_update_posted_date": "2026-03-04", "last_synced_at": "2026-10-29T20:06:47.531Z", "location_count": 1, "location_summary": "Birmingham, Alabama", "locations": [ { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT07044544" }, { "nct_id": "NCT07148947", "title": "Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative Neoplasms", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Accelerated Phase Myeloproliferative Neoplasm", "Blast Phase Myeloproliferative Neoplasm" ], "interventions": [ { "name": "Pacritinib", "type": "DRUG" }, { "name": "Decitabine", "type": "DRUG" }, { "name": "Decitabine and Cedazuridine", "type": "DRUG" }, { "name": "Azacitidine", "type": "DRUG" }, { "name": "Survey Administration", "type": "OTHER" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "OTHER", "PROCEDURE" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2026-03-02", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2026-08-19", "last_synced_at": "2026-10-29T20:06:47.531Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT07148947" }, { "nct_id": "NCT04391049", "title": "Testing the Addition of the Anti-cancer Viral Therapy Telomelysin™ to Chemoradiation for Patients With Advanced Esophageal Cancer and Are Not Candidates for Surgery", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Esophageal Adenocarcinoma", "Advanced Gastroesophageal Junction Adenocarcinoma", "Clinical Stage II Esophageal Adenocarcinoma AJCC v8", "Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8", "Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8", "Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage III Esophageal Adenocarcinoma AJCC v8", "Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage II Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IIA Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage III Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage II Esophageal Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage III Esophageal Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IIIA Esophageal Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IIIB Esophageal Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Unresectable Gastroesophageal Junction Adenocarcinoma", "Squamous Cell Carcinoma", "Squamous Cell Cancer" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Telomerase-specific Type 5 Adenovirus OBP-301", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "RADIATION", "BIOLOGICAL" ], "sponsor": "NRG Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2021-12-02", "completion_date": "2029-10-06", "has_results": true, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-10-29T20:06:47.531Z", "location_count": 17, "location_summary": "Duarte, California • South Pasadena, California • Upland, California + 14 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "South Pasadena", "state": "California" }, { "city": "Upland", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Fairway", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04391049" }, { "nct_id": "NCT06787612", "title": "Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Cancer", "Fallopian Tube Cancer", "Primary Peritoneal Cancer" ], "interventions": [ { "name": "Ubamatamab", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Cemiplimab", "type": "DRUG" }, { "name": "Fianlimab", "type": "DRUG" }, { "name": "PLD", "type": "DRUG" }, { "name": "Sarilumab", "type": "DRUG" }, { "name": "REGN10597", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 297, "start_date": "2025-05-28", "completion_date": "2028-06-30", "has_results": false, "last_update_posted_date": "2026-09-14", "last_synced_at": "2026-10-29T20:06:47.531Z", "location_count": 21, "location_summary": "Birmingham, Alabama • La Jolla, California • Los Angeles, California + 17 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06787612" }, { "nct_id": "NCT02923115", "title": "Study to Assess the Safety, Pharmacokinetics/Dynamics of DS-1040b in Subjects With Acute Submassive Pulmonary Embolism", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Pulmonary Embolism", "Thrombotic Disease" ], "interventions": [ { "name": "DS-1040b", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Enoxaparin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 134, "start_date": "2016-06-23", "completion_date": "2019-08-05", "has_results": true, "last_update_posted_date": "2023-04-19", "last_synced_at": "2026-10-29T20:06:47.531Z", "location_count": 15, "location_summary": "Mobile, Alabama • Beverly Hills, California • San Diego, California + 12 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Beverly Hills", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02923115" }, { "nct_id": "NCT00697515", "title": "Safety and Efficacy Workplace Environment Study of Lisdexamfetamine Dimesylate (LDX) in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "ADHD" ], "interventions": [ { "name": "LDX", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Shire", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 142, "start_date": "2008-07-18", "completion_date": "2008-12-20", "has_results": true, "last_update_posted_date": "2021-06-09", "last_synced_at": "2026-10-29T20:06:47.531Z", "location_count": 5, "location_summary": "Little Rock, Arkansas • Irvine, California • Overland Park, Kansas + 2 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Irvine", "state": "California" }, { "city": "Overland Park", "state": "Kansas" }, { "city": "Las Vegas", "state": "Nevada" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00697515" }, { "nct_id": "NCT02286817", "title": "Phase I Single Dose, Open-Label Pharmacokinetic Study and Single-Blind, Placebo-Controlled Dose Escalation Study of NFC-1 in Adolescents With Attention-Deficit Hyperactivity Disorder", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Attention-deficit Hyperactivity Disorder (ADHD)" ], "interventions": [ { "name": "NFC-1", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Aevi Genomic Medicine, LLC, a Cerecor company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "12 Years to 17 Years" }, "enrollment_count": 30, "start_date": "2015-01", "completion_date": "2016-03", "has_results": false, "last_update_posted_date": "2025-10-21", "last_synced_at": "2026-10-29T20:06:47.531Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02286817" }, { "nct_id": "NCT00776984", "title": "Evaluation of Tiotropium 5 µg/Day Delivered Via the Respimat® Inhaler Over 48 Weeks in Patients With Severe Persistent Asthma on Top of Usual Care (Study II)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "tiotropium 5mcg/day", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 453, "start_date": "2008-10", "completion_date": null, "has_results": true, "last_update_posted_date": "2014-09-10", "last_synced_at": "2026-10-29T20:06:47.531Z", "location_count": 18, "location_summary": "Fountain Valley, California • Fresno, California • Stockton, California + 15 more", "locations": [ { "city": "Fountain Valley", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Stockton", "state": "California" }, { "city": "Waterbury", "state": "Connecticut" }, { "city": "Pensacola", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00776984" }, { "nct_id": "NCT04421248", "title": "Biomarker Validation in Motor System Physiology in Attention Deficit Hyperactivity Disorder", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Attention Deficit Hyperactivity Disorder Combined" ], "interventions": [ { "name": "Methylphenidate", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Donald Gilbert, MD, MS, FAAN, FAAP", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "8 Years", "maximum_age": "12 Years", "sex": "ALL", "summary": "8 Years to 12 Years" }, "enrollment_count": 214, "start_date": "2020-09-01", "completion_date": "2027-03-01", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-29T20:06:47.531Z", "location_count": 2, "location_summary": "Baltimore, Maryland • Cincinnati, Ohio", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04421248" }, { "nct_id": "NCT05793216", "title": "VestibulOTherapy: Vestibular Impact on Learning", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Vestibular Disorder", "Educational Problems", "Attention Deficit Disorder" ], "interventions": [ { "name": "VestibulOTherapy", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "VestibulOTherapy", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "10 Years", "sex": "ALL", "summary": "6 Years to 10 Years" }, "enrollment_count": 15, "start_date": "2023-03-07", "completion_date": "2023-10-25", "has_results": false, "last_update_posted_date": "2023-03-31", "last_synced_at": "2026-10-29T20:06:47.531Z", "location_count": 1, "location_summary": "La Crosse, Wisconsin", "locations": [ { "city": "La Crosse", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT05793216" } ] }